vs
南玻集团（CSGS）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
Pediatrix Medical Group, Inc.的季度营收约是南玻集团的1.5倍（$493.8M vs $323.1M），Pediatrix Medical Group, Inc.净利率更高（6.8% vs 2.2%，领先4.7%），南玻集团同比增速更快（2.0% vs -1.7%），过去两年南玻集团的营收复合增速更高（4.6% vs -0.1%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
CSGS vs MD — 直观对比
营收规模更大
MD
是对方的1.5倍
$323.1M
营收增速更快
CSGS
高出3.7%
-1.7%
净利率更高
MD
高出4.7%
2.2%
两年增速更快
CSGS
近两年复合增速
-0.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $493.8M |
| 净利润 | $7.0M | $33.7M |
| 毛利率 | 50.0% | — |
| 营业利润率 | 9.0% | 9.9% |
| 净利率 | 2.2% | 6.8% |
| 营收同比 | 2.0% | -1.7% |
| 净利润同比 | -79.7% | 10.5% |
| 每股收益（稀释后） | $0.24 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSMD
| Q4 25 | $323.1M | $493.8M | ||
| Q3 25 | $303.6M | $492.9M | ||
| Q2 25 | $297.1M | $468.8M | ||
| Q1 25 | $299.5M | $458.4M | ||
| Q4 24 | $316.7M | $502.4M | ||
| Q3 24 | $295.1M | $511.2M | ||
| Q2 24 | $290.3M | $504.3M | ||
| Q1 24 | $295.1M | $495.1M |
净利润CSGSMD
| Q4 25 | $7.0M | $33.7M | ||
| Q3 25 | $20.5M | $71.7M | ||
| Q2 25 | $12.3M | $39.3M | ||
| Q1 25 | $16.1M | $20.7M | ||
| Q4 24 | $34.5M | $30.5M | ||
| Q3 24 | $19.1M | $19.4M | ||
| Q2 24 | $13.8M | $-153.0M | ||
| Q1 24 | $19.5M | $4.0M |
毛利率CSGSMD
| Q4 25 | 50.0% | — | ||
| Q3 25 | 48.1% | — | ||
| Q2 25 | 49.5% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | 51.3% | — | ||
| Q3 24 | 49.4% | — | ||
| Q2 24 | 47.3% | — | ||
| Q1 24 | 46.5% | — |
营业利润率CSGSMD
| Q4 25 | 9.0% | 9.9% | ||
| Q3 25 | 10.0% | 13.8% | ||
| Q2 25 | 10.0% | 12.8% | ||
| Q1 25 | 9.8% | 7.0% | ||
| Q4 24 | 13.4% | 7.8% | ||
| Q3 24 | 10.8% | 6.6% | ||
| Q2 24 | 8.8% | -31.3% | ||
| Q1 24 | 10.8% | 3.2% |
净利率CSGSMD
| Q4 25 | 2.2% | 6.8% | ||
| Q3 25 | 6.7% | 14.5% | ||
| Q2 25 | 4.1% | 8.4% | ||
| Q1 25 | 5.4% | 4.5% | ||
| Q4 24 | 10.9% | 6.1% | ||
| Q3 24 | 6.5% | 3.8% | ||
| Q2 24 | 4.8% | -30.3% | ||
| Q1 24 | 6.6% | 0.8% |
每股收益（稀释后）CSGSMD
| Q4 25 | $0.24 | $0.40 | ||
| Q3 25 | $0.73 | $0.84 | ||
| Q2 25 | $0.44 | $0.46 | ||
| Q1 25 | $0.57 | $0.24 | ||
| Q4 24 | $1.20 | $0.37 | ||
| Q3 24 | $0.67 | $0.23 | ||
| Q2 24 | $0.48 | $-1.84 | ||
| Q1 24 | $0.68 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $375.2M |
| 总债务越低越好 | $539.5M | $570.5M |
| 股东权益账面价值 | $283.7M | $865.9M |
| 总资产 | $1.5B | $2.2B |
| 负债/权益比越低杠杆越低 | 1.90× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资CSGSMD
| Q4 25 | $180.0M | $375.2M | ||
| Q3 25 | $158.4M | $340.1M | ||
| Q2 25 | $145.9M | $224.7M | ||
| Q1 25 | $136.0M | $99.0M | ||
| Q4 24 | $161.8M | $229.9M | ||
| Q3 24 | $118.4M | $103.8M | ||
| Q2 24 | $110.4M | $19.4M | ||
| Q1 24 | $120.8M | $8.0M |
总债务CSGSMD
| Q4 25 | $539.5M | $570.5M | ||
| Q3 25 | $538.6M | $577.2M | ||
| Q2 25 | $537.8M | $583.9M | ||
| Q1 25 | $537.6M | $590.5M | ||
| Q4 24 | $538.5M | $597.1M | ||
| Q3 24 | $539.5M | — | ||
| Q2 24 | $540.5M | — | ||
| Q1 24 | $541.5M | — |
股东权益CSGSMD
| Q4 25 | $283.7M | $865.9M | ||
| Q3 25 | $289.5M | $890.7M | ||
| Q2 25 | $290.7M | $833.8M | ||
| Q1 25 | $283.1M | $789.2M | ||
| Q4 24 | $282.6M | $764.9M | ||
| Q3 24 | $288.4M | $732.5M | ||
| Q2 24 | $273.3M | $706.5M | ||
| Q1 24 | $269.3M | $856.2M |
总资产CSGSMD
| Q4 25 | $1.5B | $2.2B | ||
| Q3 25 | $1.5B | $2.2B | ||
| Q2 25 | $1.4B | $2.1B | ||
| Q1 25 | $1.4B | $2.0B | ||
| Q4 24 | $1.5B | $2.2B | ||
| Q3 24 | $1.4B | $2.1B | ||
| Q2 24 | $1.4B | $2.0B | ||
| Q1 24 | $1.3B | $2.2B |
负债/权益比CSGSMD
| Q4 25 | 1.90× | 0.66× | ||
| Q3 25 | 1.86× | 0.65× | ||
| Q2 25 | 1.85× | 0.70× | ||
| Q1 25 | 1.90× | 0.75× | ||
| Q4 24 | 1.91× | 0.78× | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 2.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | — |
| 自由现金流率自由现金流/营收 | 17.3% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 8.46× | 3.39× |
| 过去12个月自由现金流最近4个季度 | $141.4M | — |
8季度趋势，按日历期对齐
经营现金流CSGSMD
| Q4 25 | $59.2M | $114.1M | ||
| Q3 25 | $47.9M | $137.3M | ||
| Q2 25 | $37.3M | $137.2M | ||
| Q1 25 | $11.5M | $-117.5M | ||
| Q4 24 | $82.5M | $133.0M | ||
| Q3 24 | $39.5M | $91.8M | ||
| Q2 24 | $43.1M | $107.0M | ||
| Q1 24 | $-29.4M | $-125.2M |
自由现金流CSGSMD
| Q4 25 | $55.8M | — | ||
| Q3 25 | $43.9M | — | ||
| Q2 25 | $34.6M | — | ||
| Q1 25 | $7.1M | — | ||
| Q4 24 | $76.6M | — | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $38.8M | — | ||
| Q1 24 | $-34.1M | — |
自由现金流率CSGSMD
| Q4 25 | 17.3% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 11.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 13.4% | — | ||
| Q1 24 | -11.6% | — |
资本支出强度CSGSMD
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.6% | — |
现金转化率CSGSMD
| Q4 25 | 8.46× | 3.39× | ||
| Q3 25 | 2.34× | 1.91× | ||
| Q2 25 | 3.04× | 3.49× | ||
| Q1 25 | 0.71× | -5.66× | ||
| Q4 24 | 2.39× | 4.36× | ||
| Q3 24 | 2.07× | 4.72× | ||
| Q2 24 | 3.12× | — | ||
| Q1 24 | -1.51× | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
